Kiren Naidoo is the CEO and Board Member of Zdravlje A.D., one of the largest pharmaceutical manufactures in the region.  Zdravlje was founded in 1953 and today supplies nearly 40 markets around the world (including former Yugoslavia, UK, Europe, Latin America, Asia-Pacific and Africa) with high quality biopharmaceuticals, either independently or on behalf of multinational companies.  Kiren represents Frontier Baystone, Zdravlje’s shareholders, which is a London-based specialised healthcare investor.  Frontier Baystone is led by a group of well-known industry veterans (based in the US, UK and Turkey) who were responsible for building industry-leading multinational pharmaceutical and biotechnology companies (e.g. IVAX, SICOR, MN Pharma) which were eventually acquired by major pharma companies for over $ 10 billion in collective value.

Frontier Baystone acquired Zdravlje from Teva Pharmaceutical (multinational pharmaceutical company) in April 2021 and is embarking on a growth strategy that will transform Zdravlje into a leading global supplier of high quality medicines to address serious diseases.

Previously, Kiren was an investment banker at Bank of America Merrill Lynch (BofAML), specialising in mergers & acquisitions (M&A) and financing projects within the pharmaceutical industry.  During his time at BofAML Kiren advised and executed over $50 billion in transactions across the US, Europe, CEE, Middle East and Africa.